ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2a kinases

Science Signaling

Volumn 9, Issue 415, 2016, Pages

  Kline, C Leah B ^a,b   Van Den Heuvel, A Pieter J ^a,d   Allen, Joshua E ^a,c   Prabhu, Varun V ^a,b   Dicker, David T ^a,b   El Deiry, Wafik S ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Oncoceutics   (United States)

^d Vironika   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; CYCLIN D1; DEATH RECEPTOR 5; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; ONC 201; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ATF4 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE R; TIC10 COMPOUND; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL STIMULATION; CELL STRESS; CONTROLLED STUDY; CYTOTOXICITY; DEPHOSPHORYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; CELL LINE, TUMOR; EIF-2 KINASE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959077995     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aac4374     Document Type: Article

References (45)

1. A. Ashkenazi, R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. H. Schwall, Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162 (1999).
2. J. Lemke, S. von Karstedt, J. Zinngrebe, H. Walczak, Getting TRAIL back on track for cancer therapy. Cell Death Differ. 21, 1350-1364 (2014).
3. M. S. Merchant, J. I. Geller, K. Baird, A. J. Chou, S. Galli, A. Charles, M. Amaoko, E. H. Rhee, A. Price, L. H. Wexler, P. A. Meyers, B. C. Widemann, M. Tsokos, C. L. Mackall, Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J. Clin. Oncol. 30, 4141-4147 (2012).
4. K. W. Wagner, E. A. Punnoose, T. Januario, D. A. Lawrence, R. M. Pitti, K. Lancaster, D. Lee, M. von Goetz, S. F. Yee, K. Totpal, L. Huw, V. Katta, G. Cavet, S. G. Hymowitz, L. Amler, A. Ashkenazi, Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13, 1070-1077 (2007).
5. M. Lu, D. A. Lawrence, S. Marsters, D. Acosta-Alvear, P. Kimmig, A. S. Mendez, A. W. Paton, J. C. Paton, P. Walter, A. Ashkenazi, Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 345, 98-101 (2014).
6. S. C. Cazanave, J. L. Mott, S. F. Bronk, N. W. Werneburg, C. D. Fingas, X. W. Meng, N. Finnberg, W. S. El-Deiry, S. H. Kaufmann, G. J. Gores, Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J. Biol. Chem. 286, 39336-39348 (2011).
7. G. Wang, X. Wang, H. Yu, S. Wei, N. Williams, D. L. Holmes, R. Halfmann, J. Naidoo, L. Wang, L. Li, S. Chen, P. Harran, X. Lei, X. Wang, Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat. Chem. Biol. 9, 84-89 (2013).
8. J. E. Allen, G. Krigsfeld, P. A. Mayes, L. Patel, D. T. Dicker, A. S. Patel, N. G. Dolloff, E. Messaris, K. A. Scata, W. Wang, J.-Y. Zhou, G. S. Wu, W. S. El-Deiry, Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci. Transl. Med. 5, 171ra117 (2013).
9. H. Ait Ghezala, B. Jolles, S. Salhi, K. Castrillo, W. Carpentier, N. Cagnard, A. Bruhat, P. Fafournoux, O. Jean-Jean, Translation termination efficiency modulates ATF4 response by regulating ATF4 mRNA translation at 5' short ORFs. Nucleic Acids Res. 40, 9557-9570 (2012).
10. J. Han, S. H. Back, J. Hur, Y.-H. Lin, R. Gildersleeve, J. Shan, C. L. Yuan, D. Krokowski, S. Wang, M. Hatzoglou, M. S. Kilberg, M. A. Sartor, R. J. Kaufman, ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol. 15, 481-490 (2013).
11. H. Zinszner, M. Kuroda, X.Wang, N.Batchvarova, R. T. Lightfoot, H. Remotti, J. L. Stevens, D. Ron, CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12, 982-995 (1998).
12. H. P. Harding, Y. Zhang, H. Zeng, I. Novoa, P. D. Lu, M. Calfon, N. Sadri, C. Yun, B. Popko, R. Paules, D. F. Stojdl, J. C. Bell, T. Hettmann, J. M. Leiden, D. Ron, An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619-633 (2003).
13. N. Ohoka, S. Yoshii, T. Hattori, K. Onozaki, H. Hayashi, TRB3, a novel ER stressinducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 24, 1243-1255 (2005).
14. K. Du, S. Herzig, R. N. Kulkarni, M. Montminy, TRB3: A tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300, 1574-1577 (2003).
15. E. Kiss-Toth, S. M. Bagstaff, H. Y. Sung, V. Jozsa, C. Dempsey, J. C. Caunt, K. M. Oxley, D. H. Wyllie, T. Polgar, M. Harte, L. A. J. O'Neill, E. E. Qwarnstrom, S. K. Dower, Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J. Biol. Chem. 279, 42703-42708 (2004).
16. J. W. Brewer, L. M. Hendershot, C. J. Sherr, J. A. Diehl, Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc. Natl. Acad. Sci. U.S.A. 96, 8505-8510 (1999).
17. T. D. Baird, R. C. Wek, Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism. Adv. Nutr. 3, 307-321 (2012).
18. A. E. Koromilas, Roles of the translation initiation factor eIF2a serine 51 phosphorylation in cancer formation and treatment. Biochim. Biophys. Acta 1849, 871-880 (2015).
19. R. B. Hamanaka, B. S. Bennett, S. B. Cullinan, J. A. Diehl, PERK and GCN2 contribute to eIF2a phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol. Biol. Cell 16, 5493-5501 (2005).
20. J. F. Raven, D. Baltzis, S. Wang, Z. Mounir, A. I. Papadakis, H. Q. Gao, A. E. Koromilas, PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2a phosphorylation. J. Biol. Chem. 283, 3097-3108 (2008).
21. C.-P. Ng, A. Zisman, B. Bonavida, Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. Prostate 53, 286-299 (2002).
22. E. H. Kim, S. U. Kim, D. Y. Shin, K. S. Choi, Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23, 446-456 (2004).
23. J. Ishizawa, K. Kojima, D. Chachad, P. Ruvolo, V. Ruvolo, R. O. Jacamo, G. Borthakur, H. Mu, Z. Zeng, Y. Tabe, J. E. Allen, Z.Wang, W. Ma, H. C. Lee, R. Orlowski, D. D. Sarbassov, P. L. Lorenzi, X. Huang, S. S. Neelapu, T. McDonnell, R. N. Miranda, M. Wang, H. Kantarjian, M. Konopleva, R. E. Davis, M. Andreeff, ATF4 induction through an atypical integrated stress response to ONC201 induces p53-independent apoptosis in hematological malignancies. Sci. Signal. 9, ra17 (2016).
24. L. R. G. Pike, D. C. Singleton, F. Buffa, O. Abramczyk, K. Phadwal, J.-L. Li, A. K. Simon, J. T. Murray, A. L. Harris, Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochem. J. 449, 389-400 (2013).
25. W. B'Chir, A.-C. Maurin, V. Carraro, J. Averous, C. Jousse, Y. Muranishi, L. Parry, G. Stepien, P. Fafournoux, A. Bruhat, The eIF2a/ATF4 pathway is essential for stressinduced autophagy gene expression. Nucleic Acids Res. 41, 7683-7699 (2013).
26. K. Ameri, A. L. Harris, Activating transcription factor 4. Int. J. Biochem. Cell Biol. 40, 14-21 (2008).
27. Z. Galehdar, P. Swan, B. Fuerth, S. M. Callaghan, D. S. Park, S. P. Cregan, Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOPmediated induction of the Bcl-2 homology 3-only member PUMA. J. Neurosci. 30, 16938-16948 (2010).
28. H. Puthalakath, L. A.O'Reilly, P.Gunn, L. Lee, P. N. Kelly, N. D. Huntington, P. D. Hughes, E. M. Michalak, J. McKimm-Breschkin, N. Motoyama, T. Gotoh, S. Akira, P. Bouillet, A. Strasser, ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129, 1337-1349 (2007).
29. P. J. Chefalo, J. Oh, M. Rafie-Kolpin, B. Kan, J.-J. Chen, Heme-regulated eIF-2a kinase purifies as a hemoprotein. Eur.J. Biochem. 258, 820-830 (1998).
30. M.-J. Fournier, C. Gareau, R. Mazroui, The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell Int. 10, 12 (2010).
31. A. Yerlikaya, S. R. Kimball, B. A. Stanley, Phosphorylation of eIF2a in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. Biochem. J. 412, 579-588 (2008).
32. E. McEwen, N. Kedersha, B. Song, D. Scheuner, N. Gilks, A. Han, J.-J. Chen, P. Anderson, R. J. Kaufman, Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. J. Biol. Chem. 280, 16925-16933 (2005).
33. T. Chen, D. Ozel, Y. Qiao, F. Harbinski, L. Chen, S. Denoyelle, X. He, N. Zvereva, J. G. Supko, M. Chorev, J. A. Halperin, B. H. Aktas, Chemical genetics identify eIF2a kinase heme-regulated inhibitor as an anticancer target. Nat. Chem. Biol. 7, 610-616 (2011).
34. T. Chen, K. Takrouri, S. Hee-Hwang, S. Rana, R. Yefidoff-Freedman, J. Halperin, A. Natarajan, C. Morisseau, B. Hammock, M. Chorev, B. H. Aktas, Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase. J. Med. Chem. 56, 9457-9470 (2013).
35. S. Nanduri, B. W. Carpick, Y. Yang, B. R. G. Williams, J. Qin, Structure of the doublestranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J. 17, 5458-5465 (1998).
36. C. E. Samuel, Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183, 1-11 (1991).
37. J. A. Marchal, G. J. Lopez, M. Peran, A. Comino, J. R. Delgado, J. A. García-García, V. Conde, F. M. Aranda, C. Rivas, M. Esteban, M. A. Garcia, The impact of PKR activation: From neurodegeneration to cancer. FASEB J 28, 1965-1974 (2014).
38. M. Zamanian-Daryoush, T. H. Mogensen, J. A. DiDonato, B. R. G. Williams, NF-kB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kB-inducing kinase and IkB kinase. Mol. Cell. Biol. 20, 1278-1290 (2000).
39. T. Nakamura, R. C. KunzC. Zhang, T. Kimura, C. L. Yuan, B. Baccaro, Y. Namiki, S. P. Gygi, G. S. Hotamisligil, A critical role for PKR complexes with TRBP in immunometabolic regulation and eIF2a phosphorylation in obesity. Cell Rep. 11, 295-307 (2015).
40. J. L. Armstrong, R. Flockhart, G. J. Veal, P. E. Lovat, C. P. F. Redfern, Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J. Biol. Chem. 285, 6091-6100 (2010).
41. D. Shenton, J. B. Smirnova, J. N. Selley, K. Carroll, S. J. Hubbard, G. D. Pavitt, M. P. Ashe, C. M. Grant, Global translational responses to oxidative stress impact upon multiple levels of protein synthesis. J. Biol. Chem. 281, 29011-29021 (2006).
42. E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr., K. P. Lee, L. H. Boise, Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916 (2006).
43. A. H. Schönthal, Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem. Pharmacol. 85, 653-666 (2013).
44. R. A. Daniels, H. Turley, F. C. Kimberley, X. S. Liu, J. Mongkolsapaya, P. Ch'en, X. N. Xu, B. Jin, F. Pezella, G. R. Screaton, Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 15, 430-438 (2005).
45. V. V. Prabhu, J. E. Allen, D. T. Dicker, W. S. El-Deiry, Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/ TRAIL-dependent manner. Cancer Res. 75, 1423-1432 (2015).